Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 22, 2008

Pfizer Taps Aureon to Evaluate Prostate Cancer Patients’ Response to Hormone Therapy

  • Aureon Laboratories will establish quantitative biometrics to assess therapeutic responses in studies focusing on prostate cancer for Pfizer. The collaboration will utilize Aureon’s integrated systems pathology approach, whereby data generated from tissue morphometry, multiplexed-protein biomarkers, and in situ RNA expression are integrated with patient clinical information and associated with clinical outcome.

    The deal is an extension of a previous study performed by Aureon and Pfizer to evaluate prostatectomy samples from patients treated with neo-adjuvant androgen deprivation therapy (ADT).

    Aureon technology is also being used to develop Prostate Px+. This prognosticwill be used in men newly diagnosed with prostate cancer. The companies expect the product to be released this year.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »